select trial semaglutide cardiovascular outcomes without diabetes 2023 of and tirzepatide for patients with type 2 in clinical practice AHA 23 Late-Breaker Discussion: The
Description
( ):

The improvement persisted regardless of CPAP use, though combination therapy (semaglutide plus CPAP) showed the fastest results

In new results released last week on type 2 diabetes, with which patients tend to lose less weight with medications, Lilly said the drug lowered A1C blood sugar levels by an average of 1.7% to 2% at 40 weeks and produced average weight loss of up to 17%, or nearly 17kg

In patients with T2DM and chronic liver disease attributed to MASLD, the risk of major adverse liver outcomes after GLP-1RA treatment over 10 years fails to decrease (15.8% vs

Alternative weight loss medications If the regulatory uncertainty around compounded tirzepatide concerns you, it is worth knowing about other options in the weight management space